国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2014年
17期
1295-1297
,共3页
王恒瑜%杨彦平%余毅%马小安
王恆瑜%楊彥平%餘毅%馬小安
왕항유%양언평%여의%마소안
慢性阻塞性肺疾病%罗氟司特%治疗效果
慢性阻塞性肺疾病%囉氟司特%治療效果
만성조새성폐질병%라불사특%치료효과
Chronic obstructive pulmonary disease%Roflumilast%Treatment effect
目的 分析罗氟司特对COPD的临床疗效和安全性.方法 选取2011年5月-2013年5月间的COPD患者76例,按照患者接受治疗的意愿随机分为对照组和实验组2组.给予对照组患者常规临床治疗,而实验组患者于常规治疗基础上采取罗氟司特药物治疗,对2种治疗方式的临床疗效情况和安全性进行比较分析.结果 实验组中COPD患者的临床疾病治疗总有效率97.37％明显高于对照组84.21％,P＜0.05.实验组各肺功能和血气指标明显优于治疗前(P＜0.05),而对照组则无明显改善.实验组在治疗后SGRQ评分呼吸症状、活动受限、疾病影响各部分积分和总积分均出现明显下降(P ＜0.05),但对照组变化不明显.从安全性来看,两组均无严重不良反应出现,实验组有1例出现腹泻,1例出现失眠;对照组有1例出现恶心,1例出现腹泻,2组对比差异无统计学意义(P＞0.05).结论 于常规临床治疗基础上给予COPD患者罗氟司特药物治疗能有效改善患者临床疗效,安全性高,值得临床积极推广使用.
目的 分析囉氟司特對COPD的臨床療效和安全性.方法 選取2011年5月-2013年5月間的COPD患者76例,按照患者接受治療的意願隨機分為對照組和實驗組2組.給予對照組患者常規臨床治療,而實驗組患者于常規治療基礎上採取囉氟司特藥物治療,對2種治療方式的臨床療效情況和安全性進行比較分析.結果 實驗組中COPD患者的臨床疾病治療總有效率97.37％明顯高于對照組84.21％,P＜0.05.實驗組各肺功能和血氣指標明顯優于治療前(P＜0.05),而對照組則無明顯改善.實驗組在治療後SGRQ評分呼吸癥狀、活動受限、疾病影響各部分積分和總積分均齣現明顯下降(P ＜0.05),但對照組變化不明顯.從安全性來看,兩組均無嚴重不良反應齣現,實驗組有1例齣現腹瀉,1例齣現失眠;對照組有1例齣現噁心,1例齣現腹瀉,2組對比差異無統計學意義(P＞0.05).結論 于常規臨床治療基礎上給予COPD患者囉氟司特藥物治療能有效改善患者臨床療效,安全性高,值得臨床積極推廣使用.
목적 분석라불사특대COPD적림상료효화안전성.방법 선취2011년5월-2013년5월간적COPD환자76례,안조환자접수치료적의원수궤분위대조조화실험조2조.급여대조조환자상규림상치료,이실험조환자우상규치료기출상채취라불사특약물치료,대2충치료방식적림상료효정황화안전성진행비교분석.결과 실험조중COPD환자적림상질병치료총유효솔97.37％명현고우대조조84.21％,P＜0.05.실험조각폐공능화혈기지표명현우우치료전(P＜0.05),이대조조칙무명현개선.실험조재치료후SGRQ평분호흡증상、활동수한、질병영향각부분적분화총적분균출현명현하강(P ＜0.05),단대조조변화불명현.종안전성래간,량조균무엄중불량반응출현,실험조유1례출현복사,1례출현실면;대조조유1례출현악심,1례출현복사,2조대비차이무통계학의의(P＞0.05).결론 우상규림상치료기출상급여COPD환자라불사특약물치료능유효개선환자림상료효,안전성고,치득림상적겁추엄사용.
Objective To analysis the clinical efficacy and safety of luo fluorine division for chronic obstructive pulmonary disease (COPD).Methods In May 2011 to May 2013,76 patients with COPD,according to the wishes of patients treated were randomly divided into control group and experimental group two groups.Gave control group routine clinical treatment,and based on the conventional treatment group patients taking fluorine exeter,drug therapy,then obseved the clinical efficacy and safety of two kinds of treatments for comparative.Results The patients with COPD in the clinical disease treatment was significantly higher than the control group total effective rate 97.37 ％,84.21％,P ＜0.05.Group is obviously better than the lung function and blood gas index before treatment (P ＜ 0.05),while the control group,no significant improvement.Experimental SGRQ scores after treatment of respiratory symptoms,limited activity,diseases affect each part integral and total integral are significantly decreased (P ＜0.05),but does not change significantly in the control group.From the point of safety,two groups had no serious adverse reactions occur,the experimental group has 1 case appeared diarrhea,1 case of insomnia.Control group 1 case of nausea,1 case appeared diarrhea,compared the two groups,there was no significant difference (P ＞0.05).Conclusions Based on the conventional clinical treatment for patients with COPD,fluorine forrest can drug therapy can effectively improve the clinical curative effect,high safety,worth clinical actively promote the use.
